HEADER TRANSFERASE/TRANSFERASE INHIBITOR 14-DEC-15 5FBO TITLE BTK-INHIBITOR CO-STRUCTURE COMPND MOL_ID: 1; COMPND 2 MOLECULE: TYROSINE-PROTEIN KINASE BTK; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: PROTEIN KINASE DOMAIN (UNP RESIDUES 389-659); COMPND 5 SYNONYM: AGAMMAGLOBULINEMIA TYROSINE KINASE,ATK,B-CELL PROGENITOR COMPND 6 KINASE,BPK,BRUTON TYROSINE KINASE; COMPND 7 EC: 2.7.10.2; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: BTK, AGMX1, ATK, BPK; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 9 EXPRESSION_SYSTEM_CELL_LINE: SF21; SOURCE 10 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS KEYWDS KINASE, PHOSPHATASE, TRANSFERASE-TRANSFERASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR T.O.FISCHMANN REVDAT 4 06-MAR-24 5FBO 1 REMARK REVDAT 3 18-APR-18 5FBO 1 JRNL REVDAT 2 22-NOV-17 5FBO 1 REMARK REVDAT 1 23-MAR-16 5FBO 0 JRNL AUTH J.LIU,D.GUIADEEN,A.KRIKORIAN,X.GAO,J.WANG,S.B.BOGA, JRNL AUTH 2 A.B.ALHASSAN,Y.YU,H.VACCARO,S.LIU,C.YANG,H.WU,A.COOPER, JRNL AUTH 3 J.DE MAN,A.KAPTEIN,K.MALONEY,V.HORNAK,Y.D.GAO,T.O.FISCHMANN, JRNL AUTH 4 H.RAAIJMAKERS,D.VU-PHAM,J.PRESLAND,M.MANSUETO,Z.XU, JRNL AUTH 5 E.LECCESE,J.ZHANG-HOOVER,I.KNEMEYER,C.G.GARLISI,N.BAYS, JRNL AUTH 6 P.STIVERS,P.E.BRANDISH,A.HICKS,R.KIM,J.A.KOZLOWSKI JRNL TITL DISCOVERY OF 8-AMINO-IMIDAZO[1,5-A]PYRAZINES AS REVERSIBLE JRNL TITL 2 BTK INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS. JRNL REF ACS MED CHEM LETT V. 7 198 2016 JRNL REFN ISSN 1948-5875 JRNL PMID 26985298 JRNL DOI 10.1021/ACSMEDCHEMLETT.5B00463 REMARK 2 REMARK 2 RESOLUTION. 1.89 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.2 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.89 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 38.08 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.1 REMARK 3 NUMBER OF REFLECTIONS : 23673 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.212 REMARK 3 R VALUE (WORKING SET) : 0.211 REMARK 3 FREE R VALUE : 0.236 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.020 REMARK 3 FREE R VALUE TEST SET COUNT : 1188 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 12 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.89 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 1.97 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.08 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2673 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2232 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2540 REMARK 3 BIN R VALUE (WORKING SET) : 0.2228 REMARK 3 BIN FREE R VALUE : 0.2301 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.98 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 133 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2082 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 79 REMARK 3 SOLVENT ATOMS : 86 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 34.15 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 44.30 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.36070 REMARK 3 B22 (A**2) : -4.71290 REMARK 3 B33 (A**2) : 4.35220 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.240 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.157 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.137 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.238 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.137 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.940 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.924 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 4322 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 7783 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 965 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 53 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 615 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 4322 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 265 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 4751 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.03 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.49 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 14.39 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 5FBO COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 15-DEC-15. REMARK 100 THE DEPOSITION ID IS D_1000215968. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 10-AUG-12 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.0-6.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0000 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AUTOPROC, SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 23720 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.894 REMARK 200 RESOLUTION RANGE LOW (A) : 38.100 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 200 DATA REDUNDANCY : 6.200 REMARK 200 R MERGE (I) : 0.06000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 18.2000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.89 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.90 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.6 REMARK 200 DATA REDUNDANCY IN SHELL : 6.00 REMARK 200 R MERGE FOR SHELL (I) : 0.63500 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.700 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: BUSTER REMARK 200 STARTING MODEL: IN-HOUSE STRUCTURE REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.08 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.28 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 5.5 V/V PEG 10000, 0.1M AMMONIUM REMARK 280 ACETATE, 0.1M BIS-TRIS CL PH 6.5, 2.5 MM(S)-4-(8-AMINO-3-(1-(4- REMARK 280 (DIMETHYLAMINO)BUTANOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1- REMARK 280 YL)-N-(THIAZOL-2-YL)BENZAMIDE, PH 5.5, VAPOR DIFFUSION, HANGING REMARK 280 DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X+1/2,Y+1/2,-Z REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 36.19500 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 52.23500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 36.19500 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 52.23500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 389 REMARK 465 LEU A 390 REMARK 465 GLY A 391 REMARK 465 ARG A 544 REMARK 465 TYR A 545 REMARK 465 VAL A 546 REMARK 465 LEU A 547 REMARK 465 ASP A 548 REMARK 465 ASP A 549 REMARK 465 GLU A 550 REMARK 465 TYR A 551 REMARK 465 THR A 552 REMARK 465 SER A 553 REMARK 465 SER A 554 REMARK 465 VAL A 555 REMARK 465 GLY A 556 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 SER A 543 C O CB OG REMARK 470 SER A 557 N CB OG REMARK 470 SER A 659 C O CB OG REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PHE A 413 -22.92 111.76 REMARK 500 MET A 437 -101.14 -88.69 REMARK 500 SER A 438 173.71 173.91 REMARK 500 GLU A 439 175.43 -33.06 REMARK 500 ILE A 443 36.30 -76.10 REMARK 500 LYS A 466 49.30 -84.77 REMARK 500 GLN A 467 160.72 172.22 REMARK 500 ARG A 520 -12.43 71.35 REMARK 500 ASP A 521 44.83 -142.43 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 5WH A 1001 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 5WE A 1002 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 5FBN RELATED DB: PDB DBREF 5FBO A 389 659 UNP Q06187 BTK_HUMAN 389 659 SEQRES 1 A 271 GLY LEU GLY TYR GLY SER TRP GLU ILE ASP PRO LYS ASP SEQRES 2 A 271 LEU THR PHE LEU LYS GLU LEU GLY THR GLY GLN PHE GLY SEQRES 3 A 271 VAL VAL LYS TYR GLY LYS TRP ARG GLY GLN TYR ASP VAL SEQRES 4 A 271 ALA ILE LYS MET ILE LYS GLU GLY SER MET SER GLU ASP SEQRES 5 A 271 GLU PHE ILE GLU GLU ALA LYS VAL MET MET ASN LEU SER SEQRES 6 A 271 HIS GLU LYS LEU VAL GLN LEU TYR GLY VAL CYS THR LYS SEQRES 7 A 271 GLN ARG PRO ILE PHE ILE ILE THR GLU TYR MET ALA ASN SEQRES 8 A 271 GLY CYS LEU LEU ASN TYR LEU ARG GLU MET ARG HIS ARG SEQRES 9 A 271 PHE GLN THR GLN GLN LEU LEU GLU MET CYS LYS ASP VAL SEQRES 10 A 271 CYS GLU ALA MET GLU TYR LEU GLU SER LYS GLN PHE LEU SEQRES 11 A 271 HIS ARG ASP LEU ALA ALA ARG ASN CYS LEU VAL ASN ASP SEQRES 12 A 271 GLN GLY VAL VAL LYS VAL SER ASP PHE GLY LEU SER ARG SEQRES 13 A 271 TYR VAL LEU ASP ASP GLU TYR THR SER SER VAL GLY SER SEQRES 14 A 271 LYS PHE PRO VAL ARG TRP SER PRO PRO GLU VAL LEU MET SEQRES 15 A 271 TYR SER LYS PHE SER SER LYS SER ASP ILE TRP ALA PHE SEQRES 16 A 271 GLY VAL LEU MET TRP GLU ILE TYR SER LEU GLY LYS MET SEQRES 17 A 271 PRO TYR GLU ARG PHE THR ASN SER GLU THR ALA GLU HIS SEQRES 18 A 271 ILE ALA GLN GLY LEU ARG LEU TYR ARG PRO HIS LEU ALA SEQRES 19 A 271 SER GLU LYS VAL TYR THR ILE MET TYR SER CYS TRP HIS SEQRES 20 A 271 GLU LYS ALA ASP GLU ARG PRO THR PHE LYS ILE LEU LEU SEQRES 21 A 271 SER ASN ILE LEU ASP VAL MET ASP GLU GLU SER HET 5WH A1001 42 HET 5WE A1002 37 HETNAM 5WH 4-[8-AZANYL-3-[(3~{R},6~{S})-1-CYCLOPROPYLCARBONYL-6- HETNAM 2 5WH METHYL-PIPERIDIN-3-YL]IMIDAZO[1,5-A]PYRAZIN-1-YL]-3- HETNAM 3 5WH FLUORANYL-~{N}-[4-(TRIFLUOROMETHYL)PYRIDIN-2- HETNAM 4 5WH YL]BENZAMIDE HETNAM 5WE 4-[8-AZANYL-3-[(2~{S})-1-[4-(DIMETHYLAMINO) HETNAM 2 5WE BUTANOYL]PYRROLIDIN-2-YL]IMIDAZO[1,5-A]PYRAZIN-1-YL]- HETNAM 3 5WE ~{N}-(1,3-THIAZOL-2-YL)BENZAMIDE FORMUL 2 5WH C29 H27 F4 N7 O2 FORMUL 3 5WE C26 H30 N8 O2 S FORMUL 4 HOH *86(H2 O) HELIX 1 AA1 TYR A 392 GLU A 396 5 5 HELIX 2 AA2 ASP A 398 LYS A 400 5 3 HELIX 3 AA3 GLU A 439 PHE A 442 5 4 HELIX 4 AA4 ILE A 443 LEU A 452 1 10 HELIX 5 AA5 LEU A 482 GLU A 488 1 7 HELIX 6 AA6 MET A 489 ARG A 492 5 4 HELIX 7 AA7 GLN A 494 LYS A 515 1 22 HELIX 8 AA8 ALA A 523 ARG A 525 5 3 HELIX 9 AA9 PRO A 560 SER A 564 5 5 HELIX 10 AB1 PRO A 565 SER A 572 1 8 HELIX 11 AB2 SER A 575 SER A 592 1 18 HELIX 12 AB3 THR A 602 GLN A 612 1 11 HELIX 13 AB4 SER A 623 CYS A 633 1 11 HELIX 14 AB5 LYS A 637 ARG A 641 5 5 HELIX 15 AB6 THR A 643 SER A 659 1 17 SHEET 1 AA1 5 LEU A 402 GLY A 411 0 SHEET 2 AA1 5 GLY A 414 TRP A 421 -1 O TYR A 418 N LYS A 406 SHEET 3 AA1 5 TYR A 425 MET A 431 -1 O MET A 431 N VAL A 415 SHEET 4 AA1 5 PHE A 471 THR A 474 -1 O THR A 474 N ALA A 428 SHEET 5 AA1 5 LEU A 460 CYS A 464 -1 N GLY A 462 O ILE A 473 SHEET 1 AA2 3 GLY A 480 CYS A 481 0 SHEET 2 AA2 3 CYS A 527 VAL A 529 -1 O VAL A 529 N GLY A 480 SHEET 3 AA2 3 VAL A 535 VAL A 537 -1 O LYS A 536 N LEU A 528 CISPEP 1 ARG A 468 PRO A 469 0 -2.53 SITE 1 AC1 20 LEU A 408 VAL A 416 ALA A 428 LYS A 430 SITE 2 AC1 20 GLU A 445 ALA A 446 MET A 449 ILE A 472 SITE 3 AC1 20 THR A 474 GLU A 475 MET A 477 GLY A 480 SITE 4 AC1 20 CYS A 481 ASN A 484 LEU A 528 SER A 538 SITE 5 AC1 20 ASP A 539 LEU A 542 HOH A1130 HOH A1156 SITE 1 AC2 8 SER A 394 TRP A 395 ILE A 397 TRP A 421 SITE 2 AC2 8 TYR A 425 VAL A 427 SER A 453 TYR A 461 CRYST1 72.390 104.470 38.080 90.00 90.00 90.00 P 21 21 2 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013814 0.000000 0.000000 0.00000 SCALE2 0.000000 0.009572 0.000000 0.00000 SCALE3 0.000000 0.000000 0.026261 0.00000